Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Grace Montgomery
In line with its strategy to establish its presence in the US branded market, Aurobindo has through its subsidiary Acrotech Biopharma acquired seven marketed oncology injectables from Spectrum Pharmaceuticals in a deal worth up to US$300 million.
Prioritizing the approval of generics of medicines with little or no competition has been a key part of the FDA’s efforts to support access and reduce costs to patients; the agency has just granted Teva approval for the first generic version of Lundbeck’s Sabril (vigabatrin) 500mg tablets.
Dr Reddy’s is hit with a manufacturing setback after getting issued a Form 483 report for its site in Andhra Pradesh, India, while several firms announce site expansions, including in Spain and the US.
Two infliximab switching studies have provided reassuring data on the safety of Celltrion’s CT-P13 infliximab biosimilar to treat IBD. While one report explores changing pediatric patients to CT-P13 from the Remicade reference drug, the other looks at reverse switching patients from the biosimilar to the originator brand.
Cipla has formed a licensing agreement with Bio-Thera Solutions for the Chinese firm’s BAT1706 bevacizumab biosimilar, which the Indian company will distribute and sell in select emerging markets.
Pfizer is set to close two of its manufacturing facilities in India this year, after the firm concluded that production at the former Hospira sites “is not viable” due to falling demand.